Drug Trial Radar · NCT04960579
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
275
Planned (sponsor's estimate)
Start
May 5, 2022
Primary completion
Mar 2029
Study completion Mar 2042
Sponsor
- Lead sponsor
- Poseida Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Roche-Genentech
- First posted
- Jul 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Conditions
- Multiple Myeloma
Interventions
P-BCMA-ALLO1 CAR-T cellsBiological
Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
RimiducidDrug
Safety switch activator
MethotrexateDrug
Anti-metabolite
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Part 1: Assess the safety and maximum tolerated dose (MTD) of P-BCMA-ALLO1 based on dose limiting toxicities (DLT)Time frame: Baseline through Day 28
- Phase 1 Part 2: Assess the safety and tolerability of P-BCMA-ALLO1 when administered as a fixed dose of cells.Time frame: Baseline through 36 months
- Phase 1b: The effect of cell dose and study armTime frame: Baseline through 36 months
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Goodyear, Arizona
University of California San Diego
San Diego, California
University of California San Francisco
San Francisco, California
Emory University
Atlanta, Georgia
Blood Marrow and Transplant Group of Georgia
Atlanta, Georgia
City of Hope
Chicago, Illinois
Advocate Aurora Health
Park Ridge, Illinois
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Wayne State - Karmanos Cancer Institute
Detroit, Michigan
Hackensack Meridian Health
Hackensack, New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Mount Sinai
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
University of Cincinnati
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Oklahoma, Health Sciences Center
Oklahoma City, Oklahoma
University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Sarah Cannon Research Institute - St. David's South Austin Medical Center
Austin, Texas
Houston Methodist Research Institute
Houston, Texas
Sarah Cannon Research Institute - Methodist Healthcare
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.